Louisiana subscribes to Gilead’s Netflix-style plan for hep C; Ono is investing millions in a new I/O research alliance

→ Remember the controversy over Gilead’s big price for a hep C cure? That’s all over. In a sign of the new times, the state Louisiana is signing up for a Netflix subscription model to cover the state’s poor and prison population. They’re paying a flat fee to Asegua Therapeutics, a subsidiary of Gilead, to gain access to as much of the triple combo they need to treat some of the state’s most vulnerable residents.

Ono Pharmaceutical is making a “multimillion-pound” investment into a new discovery alliance that will align them with researchers connected to Cancer Research UK and the antibody engineers at LifeArc to go after new immunotherapy targets. CRUK’s discovery labs will handle the small molecule work. “We’re thrilled to welcome Ono to join and expand our successful collaboration with LifeArc and create one of our most ambitious alliances to date,” says Hamish Ryder, director of Cancer Research UK’s Therapeutic Discovery Labs. “This unique alliance is a melting pot of world-leading cancer research and each organisation’s extensive expertise in oncology drug discovery.”

J&J’s Janssen has submitted an sBLA for a combo of Darzalex that comprises bortezomib, thalidomide and dexamethasone in an effort to move the drug to frontline use for multiple myeloma.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->